Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Senior Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
ESG
Search
Innovation and research
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
03/04/2019
HOW THE DNA VACCINE FORMAT USED IN A NOVEL MANNER CAN GENERATE POTENT CD8-DOMINATED NEOANTIGEN-SPECIFIC T CELL RESPONSES | San Francisco, March 2019
03/04/2019
GENERATING POTENT CD8-DOMINATED NEOANTIGEN-SPECIFIC T CELL RESPONSES WITH NOVEL DNA VACCINE | San Francisco, March 2019
03/04/2019
MANUFACTURING, REGULATORY AND LOGISTICS CHALLENGES IN THE RAPIDLY EVOLVING AREA OF THE INDIVIDUALISED THERAPEUTIC CANCER VACCINES | Boston, November 2018
03/04/2019
DEVELOPMENT OF A COST-EFFECTIVE PERSONALIZED CANCER NEOANTIGEN VACCINES INDUCING A UNIQUE CD8-DOMINATED T CELL RESPONSE | Basel, October 2018
03/04/2019
INDIVIDUALISED CANCER NEOANTIGEN VACCINES | Vienna, October 2018
Pages:
1
2
3
4
5
6
7
8
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
